These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2649969)

  • 1. [HMG CoA reductase inhibitors: a new class of hypocholesterolemic agents].
    Ziegler O; Drouin P; Debry G
    Rev Prat; 1989 Feb; 39(4):313-5. PubMed ID: 2649969
    [No Abstract]   [Full Text] [Related]  

  • 2. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
    Grundy SM
    N Engl J Med; 1988 Jul; 319(1):24-33. PubMed ID: 3288867
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrates and HMG-CoA reductase inhibitors.
    Huff MW
    CMAJ; 1991 Oct; 145(8):977. PubMed ID: 1913432
    [No Abstract]   [Full Text] [Related]  

  • 6. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitors of HMG CoA reductase: new modes of action, new indications?].
    Essig M; Vrtovsnik F; Friedlander G
    Therapie; 2000; 55(1):43-9. PubMed ID: 10860000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HMA CoA reductase inhibitors].
    Kostner GM
    Wien Med Wochenschr; 1999; 149(5-6):109-10. PubMed ID: 10408000
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    al Rayyes O; Wallmark A; Florén CH
    Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
    Johnston TP; Palmer WK
    Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
    Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F
    Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGCoA reductase inhibitors.
    Naylor D; McIsaac W
    Can J Cardiol; 1993 May; 9(4):288-90. PubMed ID: 8513421
    [No Abstract]   [Full Text] [Related]  

  • 16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of cholesterol synthesizing enzymes (CSE) inhibitors].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 1999 Jun; 22(6):184-6. PubMed ID: 10394795
    [No Abstract]   [Full Text] [Related]  

  • 18. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What is assured in therapy with HMG-CoA reductase inhibitors (cholesterol synthesis inhibitors)?].
    Knisel W; Eggstein M
    Internist (Berl); 1989 Dec; 30(12):776-83. PubMed ID: 2695487
    [No Abstract]   [Full Text] [Related]  

  • 20. [Statins remain the standard. New methods for lipid lowering therapy].
    Aumiller J
    MMW Fortschr Med; 2001 Oct; 143(42):16-7. PubMed ID: 11697281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.